Hydromorphone polymer implant: A potential alternative to methadone maintenance

Journal of Substance Abuse Treatment

Volumn 14, Issue 6, 1997, Pages 535-542

  Rhodes, Deborah J ^a   Grossman, Stuart A ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Hydromorphone; Intravenous drug use; Methadone maintenance; Polymer

Indexed keywords

COCAINE; HYDROMORPHONE; METHADONE; OPIATE;

ARTICLE; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG OVERDOSE; HUMAN; HUMAN TISSUE; IMPLANTABLE PORT SYSTEM; OPIATE ADDICTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031465009     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0740-5472(97)00117-7     Document Type: Article

References (33)

1. Alcohol, Drug Abuse, and Mental Health Administration. (1991). Drug abuse treatment: An economical approach to addressing the drug problem in America. (DHHS Publication No. ADM 91-1934). Washington, DC: U.S. Government Printing Office.
2. Ball, J.C., Lange, W.R., Myers, D.P., & Friedman, S.R. ( 1988). Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior, 29, 214-226.
3. Ball, J.C., Nurco, D.N., Clayton, R.R., Lerner, M., Hagan, T.A., & Groves, G.A. (1995). Etiology, epidemiology, and natural history of heroin addiction: A social science approach. In L.S. Harris (Ed.), Problems of drug dependence, 1994. (DHHS Publication No. ADM 95-3882, pp. 74-78). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 152.
4. Ball, J.C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
5. Blaine, J.D., & Renault, P.F. (Eds.). (1976). Rx: 3x/week LAAM alternative to methadone. (DHHS Publication No. ADM 78-347). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 8.
6. Centers for Disease Control and Prevention. (1994). HIV/AIDS Surveillance Report, 6(1).
7. Des Jarlais, D.C., Joseph, H., Dole, V.P., & Nyswander, M.E. (1985). Medical maintenance feasibility study. In R.S. Ashery (Ed.), Progress in the development of cost-effective treatment for drug abusers. (DHHS Publication No. ADM 85-1401, pp. 101-110). Washington, DC: U.S. Governent Printing Office. National Institute on Drug Abuse Research Monograph, 58.
8. Dole, V.P., & Joseph, H. (1978). Long-term outcome of patients treated with methadone maintenance. Annals New York Academy of Sciences, 311, 181-189.
9. Fulco, C.E., Liverman, C.T., & Earley, L.E. (Eds.). (1994). Development of medications for the treatment of opiate and cocaine addictions: Issues for the government and private sector. Washington, DC: National Academy Press.
10. Kreek, M.J. (1983). Health consequences associated with the use of methadone. In J.R. Cooper, F. Altman, B.S. Brown, & D. Czechowicz (Eds.), Research on the treatment of narcotic addiction: State of the art. (DHHS Publication No. ADM 83-1281, pp. 456-481). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series.
11. Kreek, M.J. (1991). Using methadone effectively: Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs. In R.W. Pickens, C.G. Leukefeld, & C.R. Schuster (Eds.), Improving drug abuse treatment, 1991. (DHHS Publication No. ADM 91-1754, pp. 245-266). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 106.
12. Kreek, M.J., Wardlaw, S.L., Hartman, N., Raghunath, J., Friedman, J., Schneider, B., & Frantz, A.G. (1983). Circadian rhythms and levels of -endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sciences, 33, (Suppl. I), 409-411.
13. Lesser, G.J., Grossman, S.A., Leong, K.W., Lo, H., & Eller, S. (1996). In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain. Pain, 65, 265-272.
14. McCaul, M.E., Bigelow, G.E., Stitzer, M.L., & Liebson I. (1982). Short-term effects of oral methadone in methadone maintenance subjects. Clinical Pharmacologal and Therapeutics, 31, 753-761.
15. McLellan, A.T., Amdt. I.O, Metzger, D.S. Woody, G.E., & O'Brien. C.P. (1993). The effects of psychosocial services in substance abuse treatment. JAMA, 269, 1953-1959.
16. Newman, R.G. (1987). Methadone treatment: Defining and evaluating success. New England Journal of Medicine, 317, 447-50.
17. Novick, D.M., & Joseph, H. (1991). Medical maintenance: the treatment of opiate dependence in general medical practice. Journal of Substance Abuse Treatment, 8, 233-239.
18. Novick, D.M., Joseph, H., Croxson, T.S., Salsitz, E.A., Wang, G., Richman, B.L., Poretsky, L., Keefe, J.B., & Whimbey, E. (1990). Absence of antibody to human immunodeficiency virus in longterm, socially rehabilitated methadone maintenance patients. Archives of Internal Medicine, 150, 97-99.
19. Novick, D.M., Ochshorn, M., Ghali, V., Croxson, T.S., Mercer, W.D., Chiorazzi, N., & Kreek, M.J. (1989). Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. The Journal of Pharmcology and Experimental Therapeutics, 250, 606-610.
20. Novick, D.M., Pascarelli, E.F., Joseph, H., Salsitz, E.A., Richman, B.L., Des Jarlais, D.C., Anderson, M., Dole, V.P., & Nyswander, M.E. (1988). Methadone maintenance patients in general medical practice: A preliminary report. JAMA, 259, 3299-3302.
21. Novick, D.M., Richman, B.L., Friedman, J.M., Friedman, J.E., Fried, C., Wilson, J.P., Townley, A., & Kreek, M.J. (1993). The medical status of methadone maintenance patients in treatment for 11-18 years. Drug and Alcohol Dependence, 33, 235-245.
22. Pickens, R.W., & Fletcher, B.W. (1991 ). Overview of treatment issues. In R.W. Pickens, C.G. Leukefeld, C.R, Schuster (Eds.), Improving drug abuse treatment (DHHS Publication No. ADM 91-1754, pp. 1-19). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 106.
23. Senay, E.C., Barthwell, A.G., Marks, R., & Bokos, P. (1995). Medical maintenance: A five year experience. In L. Harris (Ed.), Problems of drug dependence, 1994 (DHHS Publication No. ADM 95-3883, p. 471). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 153.
24. Simpson, D.D. (1981). Treatment for drug abuse. Archives of General Psychiatry, 38, 875-880.
25. Simpson, D.D. (1984). National treatment system evaluation based on the Drug Abuse Reporting Program (DARP) follow up research. In F.M. Tims & J.P. Ludford (Eds.), Drug abuse treatment evaluation: Strategies, progress, and prospects. (DHHS Publication No. ADM 84-1329, pp. 1-19). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 51.
26. Stitzer, M., & Bigelow, G. (1978). Contingency management in a methadone maintenance program: Availability of reinforcers. The International Journal of the Addictions, 13, 737-746.
27. Stitzer, M.L., Bigelow, G.E., & Iguchi, M.Y. (1993). Behavioral interventions in the methadone clinic: Contingent methadone take-home incentives. In L. Harris (Ed.), Problems of drug dependence, 1992. (DHHS Publication No. ADM 93-3505, p. 66). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 132.
28. Stitzer, M.L., & Kirby, K.C. (1991). Reducing illicit drug use among methadone patients. In R.W. Pickens, C.G. Leukefeld, & C.R. Schuster (Eds.), Improving drug abuse treatment (DHHS Publication No. ADM 91-1754, pp. 178-203). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 106.
29. Tims, F.M., Fletcher, B.W., & Hubbard, R.L. (1991). Treatment outcomes for drug abuse clients. In R.W. Pickens, C.G. Leukefeld, & C.R. Schuster (Eds.), Improving drug abuse treatment. (DHHS Publication No. ADM 91-1754, pp. 93-113). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 106.
30. Vlahov, D., Anthony, J.C., Munoz, A., Margolick, J., Nelson, K.E., Celentano, D.D., Solomon, L., & Polk, B.F. (1991). The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants. In P. Hartsock & S.G. Genser (Eds.), Longitudinal studies of HIV infection in intravenous drug users: Methodological issues in natural history research. (DHHS Publication No. ADM 91-1786, pp. 75-100). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 109.
31. Wesson, D.R. (1988). Revival of medical maintenance in the treatment of heroin dependence. JAMA, 259, 3314-3315.
32. West, A.P. (1991). Drug abuse treatment as a strategy to prevent human immunodeficiency virus infection among intravenous drug users. Archives of Internal Medicine, 151, 1493-1496.
33. Woody, G.E., McLellan, A.T., O'Brien, C.P., Williams, J., Navaline, H., Dyanick, S., Metzger, D.S.. DePhilippis, D., & Druley, P. (1992). HIV sero-conversion and treatment status. In L. Harris (Ed.), Problems of drug dependence, 1991 (DHHS Publication No. ADM 92-1888, p. 303). Washington, DC: U.S. Government Printing Office. National Institute on Drug Abuse Research Monograph Series, 119.